TORONTO, July 3, 2019 /CNW/ - Kevin Sullivan, Chief Executive Officer, Appili Therapeutics Inc. (APLI), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. Headquartered in Halifax, Nova Scotia, Appili is a biopharmaceutical company focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease. Appili Therapeutics Inc. commenced trading on TSX Venture Exchange on June 25, 2019.
SOURCE TMX Group Limited
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2019/03/c0625.html
Copyright CNW Group 2019